Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

NCT06115499 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT06115499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06115499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
August 13, 2024
Completion date
December 9, 2029
Enrollment
10 (actual)
Sites
345

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic acinar cell carcinoma, pancreatic adenocarcinoma, pancreatic adenosquamous carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic squamous cell carcinoma, stage iv pancreatic cancer ajcc v8